Activation of PPAR‐γ and PTEN cascade participates in lovastatin‐mediated accelerated differentiation of oligodendrocyte progenitor cells
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Previously, we and others documented that statins including‐lovastatin (LOV) promote the differentiation of oligodendrocyte progenitor cells (OPCs) and remyelination in experimental autoimmune encephalomyelitis (EAE), an multiple sclerosis (MS) model. Conversely, some recent studies demonstrated that statins negatively influence oligodendrocyte (OL) differentiation in vitro and remyelination in a cuprizone‐CNS demyelinating model. Therefore, herein, we first investigated the cause of impaired differentiation of OLs by statins in vitro settings. Our observations indicated that the depletion of cholesterol was detrimental to LOV treated OPCs under cholesterol/serum‐deprived culture conditions similar to that were used in conflicting studies. However, the depletion of geranylgeranyl‐pp under normal cholesterol homeostasis conditions enhanced the phenotypic commitment and differentiation of LOV‐treated OPCs ascribed to inhibition of RhoA‐Rho kinase. Interestingly, this effect of LOV was associated with increased activation and expression of both PPAR‐γ and PTEN in OPCs as confirmed by various pharmacological and molecular based approaches. Furthermore, PTEN was involved in an inhibition of OPCs proliferation via PI3K‐Akt inhibition and induction of cell cycle arrest at G1 phase, but without affecting their cell survival. These effects of LOV on OPCs in vitro were absent in the CNS of normal rats chronically treated with LOV concentrations used in EAE indicating that PPAR‐γ induction in normal brain may be tightly regulated‐providing evidences that statins are therapeutically safe for humans. Collectively, these data provide initial evidence that statin‐mediated activation of the PPAR‐γ‐PTEN cascade participates in OL differentiation, thus suggesting new therapeutic‐interventions for MS or related CNS‐demyelinating diseases. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 2×
“In chronic lesions, axons are nonresponsive to OPCs (Chang et al., 2002; Dawson et al., 2000) due to the accumulation of inhibitory molecules or degraded myelin (Charles et al.”
BackgroundHigh cholesterol level is essential for myelin membrane growth
Saher, G., Brügger, B., Lappe-Siefke, C., Möbius, W., Tozawa, R.-I., Wehr, M. C., Wieland, F., Ishibashi, S., & Nave, K.-A. (2005) · Nature Neuroscience · doi:10.1038/nn1426 · Cited by 799 · cited 1×
“Since cholesterol, as the main constituent of myelin lipids produced by OLs, is required for myelin formation in the CNS (Saher et al., 2005), considering statins as MS therapeutics raise legitimate concerns.”
BackgroundMyelin Impairs CNS Remyelination by Inhibiting Oligodendrocyte Precursor Cell Differentiation
Kotter, M. R., Li, W.-W., Zhao, C., & Franklin, R. J. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2615-05.2006 · Cited by 768
Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612 · cited 1×
“These inhibitory molecules block the differentiation of OPCs into myelinating OLs (Back et al., 2005; Kotter et al., 2006) via increased activation of RhoA and protein kinase C (Baer et al., 2009).”
BackgroundMultiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574 · cited 2×
“Neurological deficits usually disap- pear in MS patients by spontaneous remyelination of axons by myelinating OLs present in acute lesions, while they persist in some patients due to failed remyelination especially in chronic lesions (Jeffery and Blakemore, 1997; Prineas et al., 1993).”
BackgroundMechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505268200 · Cited by 235 · cited 2×
“which inhibits down-stream cellular signaling (Cordle et al., 2005).”
BackgroundBernardo, A., Levi, G., & Minghetti, L. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00110.x · Cited by 222
Baer, A. S., Syed, Y. A., Kang, S. U., Mitteregger, D., Vig, R., ffrench-Constant, C., Franklin, R. J. M., Altmann, F., Lubec, G., & Kotter, M. R. (2009) · Brain · doi:10.1093/brain/awn334 · Cited by 211
Fraser, M. M., Bayazitov, I. T., Zakharenko, S. S., & Baker, S. J. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2007.10.048 · Cited by 202 · cited 2×
“Also, PTEN is reported to regulate neuronal differentiation (Lachyankar et al., 2000) and its deficiency in the brain causes defects in synaptic structure and myelination abnormalities (Fraser et al., 2008).”
BackgroundStatin Therapy Inhibits Remyelination in the Central Nervous System
Miron, V. E., Zehntner, S. P., Kuhlmann, T., Ludwin, S. K., Owens, T., Kennedy, T. E., Bedell, B. J., & Antel, J. P. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080947 · Cited by 141 · cited 2×
“In contrast, simvastatin was shown to impede the remyelination process in a cuprizone-CNS demyelinating model (non-EAE model) (Klopfleisch et al., 2008; Miron et al., 2009).”
Background
Cited by
Lin, J.-P., Mironova, Y. A., Shrager, P., & Giger, R. J. (2017) · eLife · doi:10.7554/elife.30498 · Cited by 64
Safina, D., Schlitt, F., Romeo, R., Pflanzner, T., Pietrzik, C. U., Narayanaswami, V., Edenhofer, F., & Faissner, A. (2016) · Glia · doi:10.1002/glia.23009 · Cited by 54
“differentiation presumably depend on the cholesterol concentration (Bieberich, 2012; Orth and Bellosta, 2012; Paintlia et al., 2010), we proposed that the deprivation of cholesterol might result in the impaired differentiation.”
BackgroundBaarine, M., Ragot, K., Athias, A., Nury, T., Kattan, Z., Genin, E. C., Andreoletti, P., Ménétrier, F., Riedinger, J.-M., Bardou, M., et al. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2011.10.007 · Cited by 43
Paintlia, A. S., Paintlia, M. K., Singh, A. K., & Singh, I. (2013) · Glia · doi:10.1002/glia.22537 · Cited by 43
“OPCs (2,000 cells/cm2) were plated in PDL-coated culture dishes or glass cover slips in serum-free modified Bottenstein–Sato-based medium (Bottenstein and Sato, 1979) supplemented with trophic factors, i.e., PDGF-aa and basic FGF (10 ng/mL each) as described earlier (Paintlia et al., 2010).”
BackgroundMethodInfluentialSelf-citationNeuron Membrane Trafficking and Protein Kinases Involved in Autism and ADHD
Kitagishi, Y., Minami, A., Nakanishi, A., Ogura, Y., & Matsuda, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16023095 · Cited by 37
“via the activation of the PPARγ [119].”
Metadata
- Authors
- Paintlia, A. S., Paintlia, M. K., Singh, A. K., Orak, J. K., & Singh, I.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2010-06-23
- Volume
- 58
- Issue
- 14
- Pages
- 1669-1685
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2038300711
- Cited by
- 43
- References
- 13
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of PPAR‐γ and PTEN cascade participates in lovastatin‐mediated accelerated differentiation of oligodendrocyte progenitor cells. https://app.cochat.ai/papers/10.1002/glia.21039
- The paper
- Paintlia, A. S., Paintlia, M. K., Singh, A. K., Orak, J. K., & Singh, I. (2010). Activation of PPAR‐γ and PTEN cascade participates in lovastatin‐mediated accelerated differentiation of oligodendrocyte progenitor cells. Glia. https://doi.org/10.1002/glia.21039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.